Screening for social anxiety disorder in the clinical setting: using the Liebowitz Social Anxiety Scale
Screening for social anxiety disorder in the clinical setting: using the Liebowitz Social Anxiety Scale
复制标题
DOI：
10.1016/s0887-6185(02)00134-2
复制
发表时间：
2002-01-01
影响因子：
10.3
通讯作者：
Liebowitz, MR
中科院分区：
文献类型：
--
作者：
Mennin, DS;Fresco, DM;Liebowitz, MR
目的：我们试图确定Liebowitz社交焦虑量表（LSAS）总分和子量表评分的最佳截止值，用于诊断社交焦虑障碍（SAD）和指定SAD的广义亚型。方法：来自多中心样本的364例患者根据结构化诊断访谈符合SAD标准，其中262例符合全身亚型标准，34例无当前轴I障碍的对照参与者参加了本研究。所有参与者都由一名独立的评估员进行了Liebowitz社交焦虑量表的评估。结果如下：受试者操作特征分析显示，LSAS在识别符合SAD和SAD广义亚型标准的个体方面表现良好。SAD的临界值为30，其广义亚型的LSAS总分为60，代表了特异性和敏感性的最佳平衡。结论：这些研究结果为使用Liebowitz社交焦虑量表在临床环境中识别SAD及其广义亚型的个体提供了支持。识别SAD患者应增加这些患者接受适当治疗这种损害性疾病的百分比。(C)2002年爱思唯尔科技有限公司All rights reserved.
Objective: We sought to determine optimal cutoff values for the Liebowitz Social Anxiety Scale (LSAS) total and subscale scores for the diagnosis of social anxiety disorder (SAD) and designation of the generalized subtype of SAD. Method: Three hundred and sixty-four patients from a multi-site sample who met criteria for SAD according to structured diagnostic interview, 262 of whom met criteria for the generalized subtype, and 34 control participants free of current Axis I disorders participated in this study. All participants were given the Liebowitz Social Anxiety Scale by an independent assessor. Results: Receiver Operating Characteristics analysis revealed that the LSAS performed well in identifying individuals who met criteria for SAD and for the generalized subtype of SAD. Cutoffs of 30 for SAD and 60 for its generalized subtype on the LSAS total score represented the best balance of specificity and sensitivity. Conclusions: These findings provide support for the use of the Liebowitz Social Anxiety Scale for the identification of individuals with SAD and its generalized subtype in clinical settings. Identification of patients with SAD should increase the percentage of these patients who receive appropriate treatment for this impairing disorder. (C) 2002 Elsevier Science Inc. All rights reserved.